Orforglipron

Mechanism

Orforglipron is a non-peptide, orally bioavailable small molecule that acts as a selective GLP-1 receptor agonist. Like peptide GLP-1 agonists, it stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and reduces appetite. The key distinction is its oral bioavailability — it does not require injection or cold-chain storage, potentially offering major access and convenience advantages over injectable GLP-1 therapies.

Evidence base

Phase 2 — Type 2 Diabetes

Frias et al. (2023) demonstrated significant HbA1c reductions (up to 2.1%) and weight loss (4–5 kg) with orforglipron 45 mg daily over 26 weeks in T2D patients.

Phase 2 — Obesity

Aronne et al. (2023) reported 12–15% weight loss at 36 weeks at highest doses, with a GLP-1-consistent safety profile (GI adverse events).

Phase 3 — ATTAIN Programme

ATTAIN-1 pivotal obesity trial topline results expected mid-2025 (Lilly pipeline, 2025). Most advanced oral GLP-1 in late-stage obesity development.

Evidence Grade: Moderate

Phase 2 data is peer-reviewed. Phase 3 results pending. No approved indication.

Protocols

In clinical trials, orforglipron is administered once daily as an oral tablet:

• Starting dose: 3 mg daily
• Titration: 3 → 6 → 12 → 24 → 36 → 45 mg at ~2–4 week intervals
• Target maintenance: 36 mg or 45 mg daily
• Route: Oral tablet, with or without food

These protocols reflect registered clinical trial designs. Orforglipron is not approved for use outside clinical trials. Research use only.

UK legal status

Orforglipron is an investigational medicinal product, not licensed by the MHRA, EMA, or FDA. It is legal to possess for bona fide research purposes in the UK. Any supply for human consumption would be subject to MHRA medicines regulations. Not available on UK prescription.

Vendor notes

Orforglipron is an investigational compound not commercially available through standard research peptide supply channels. No vetted UK vendor listings at this time.